The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Mineralys Therapeutics Inc shares valued at $165,931 were sold by Rodman David Malcom on Jun 13 ’25. At $14.60 per share, Rodman David Malcom sold 11,366 shares. The insider’s holdings dropped to 101,651 shares worth approximately $1.45 million following the completion of this transaction.
Also, Rodman David Malcom purchased 11,366 shares, netting a total of over 165,931 in proceeds.
Before that, Rodman David Malcom had sold 11,366 shares from its account. In a trade valued at $173,774, the Chief Medical Officer traded Mineralys Therapeutics Inc shares for $15.29 each. Upon closing the transaction, the insider’s holdings decreased to 11,366 shares, worth approximately $1.52 million.
As published in their initiating research note from Jefferies on June 11, 2025, Mineralys Therapeutics Inc [MLYS] has been a Hold and the price target has been revised to $15. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of April 02, 2024, Goldman has initiated its “Buy” rating for MLYS. Earlier on March 07, 2023, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for MLYS stock.
Analyzing MLYS Stock Performance
On last trading session,, Mineralys Therapeutics Inc [NASDAQ: MLYS] rose 0.71% to $14.24. The stock’s lowest price that day was $13.6, but it reached a high of $14.315 in the same session. During the last five days, there has been a surge of approximately 3.34%. Over the course of the year, Mineralys Therapeutics Inc shares have jumped approximately 18.27%. Shares of the company reached a 52-week high of $18.38 on 03/19/25 and a 52-week low of $8.24 on 02/25/25.
Support And Resistance Levels for Mineralys Therapeutics Inc (MLYS)
According to the 24-hour chart, there is a support level at 13.79, which, if violated, would cause prices to drop to 13.34. In the upper region, resistance lies at 14.50. The next price resistance is at 14.77. RSI (Relative Strength Index) is 44.49 on the 14-day chart, showing neutral technical sentiment.
Is Mineralys Therapeutics Inc subject to short interest?
Stocks of Mineralys Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.27 million shares to 6.16 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 6.43 million shares. A decline of -4.32% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.98 of the overall float, the days-to-cover ratio (short ratio) decline to 6.98.
Which companies own the most shares of Mineralys Therapeutics Inc (MLYS)?
In terms of Mineralys Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 45 in the next 12 months, up nearly 218.25% from the previous closing price of $14.14. Analysts anticipate Mineralys Therapeutics Inc stock to reach 48 by 2025, with the lowest price target being 42. In spite of this, 2 analysts ranked Mineralys Therapeutics Inc stock as Buy at the end of 2025. On March 07, 2023, Stifel assigned a price target of “a Buy” to the stock and initiated coverage with a $45.
